Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock.

Separately, Alliance Global Partners decreased their price target on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, August 14th.

Aspira Women’s Health Trading Up 1.3 %

Shares of NASDAQ AWH opened at $0.76 on Monday. Aspira Women’s Health has a 12-month low of $0.67 and a 12-month high of $5.65. The firm’s 50-day moving average price is $0.84 and its 200-day moving average price is $1.29. The stock has a market capitalization of $12.67 million, a price-to-earnings ratio of -0.63 and a beta of 1.44.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co purchased a new position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned about 0.19% of Aspira Women’s Health as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.